Gabapentin Capsule
Product Images NDC 70518-2970

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 300 mg capsules label showing a quantity of 30 capsules. The label indicates the product is repackaged by RemedyRepack Inc., with manufacturer ScieGen Pharmaceuticals, Inc. Directions to see package insert and storage instructions are included. The label features a QR code and NDC number 70518-2970-00.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over 8 weeks comparing Placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, starting from baseline to week 8. The y-axis displays mean pain score from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin group shows a decreasing pain score over time compared to the placebo group.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease notably in both Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the proportion of responders in two studies between placebo (PBO) and Gabapentin (GBP) at various dosages (GBP 1800, 2400, 3600 mg). Study 1 shows 12% responders for placebo and 29% for GBP 3600, while Study 2 shows 14% responders for placebo and 32% and 34% for GBP 1800 and 2400, respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

The image shows a formula for calculating creatinine clearance (CLCr), which factors in age, weight, serum creatinine levels, and includes an adjustment multiplier for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing its molecular framework with a cyclohexane ring attached to an aminomethyl group and an acetic acid moiety.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot displaying the percentage difference across three studies labeled Study a, Study b, and Study c. The x-axis represents daily dose in milligrams (600, 900, 1200, 1800 mg) and the y-axis shows difference percentage ranging from 2% to 22%. Each study's data points are marked with distinct black, grey, and white squares respectively.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.